Verona Pharma meeting its primary objective in its dose ranging Phase IIa trial of RPL554 in asthma patients is extremely encouraging and follows the unequivocally positive results from all three parts of its Phase I/IIa trial in COPD during 2015. The compound continues to demonstrate an attractive profile with its combined bronchodilator and anti-inflammatory properties, representing a novel approach to the treatment of respiratory disease. We continue to look forward to top-line data from a Ph ....
15 Mar 2016
RPL554 meets trial endpoint in asthma patients
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
RPL554 meets trial endpoint in asthma patients
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
15 Mar 2016 -
Author:
Sheena Berry -
Pages:
4
Verona Pharma meeting its primary objective in its dose ranging Phase IIa trial of RPL554 in asthma patients is extremely encouraging and follows the unequivocally positive results from all three parts of its Phase I/IIa trial in COPD during 2015. The compound continues to demonstrate an attractive profile with its combined bronchodilator and anti-inflammatory properties, representing a novel approach to the treatment of respiratory disease. We continue to look forward to top-line data from a Ph ....